Accessibility Menu
Journey Medical logo

Journey Medical(NASDAQ) DERM

Market Cap$175.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-33%
5 YearN/A
1 Year-13%
1 Month-10%
$6.40
-0.78%
-0.05Today
After hours$6.38-$0.02 (-0.31%)
Journey Medical last closing stock price
MetricPriceDate
Last closeUSD 6.372026-07-31
Journey Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.91%USD 6.192026-07-24
1 month-9.52%USD 7.042026-07-01
3 month+22.74%USD 5.192026-05-01
Year to date-17.38%USD 7.712025-12-31
1 year-13.33%USD 7.352025-07-31
3 year+231.77%USD 1.922023-08-01
Since inception-32.95%USD 9.502021-11-12

Journey Medical Financials at a Glance

Market Cap

$175.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$64.68M

Net Income (TTM)

-$9.59M

EPS (TTM)

-$0.38

P/E Ratio

-16.62

Dividend

$0.00

Beta (Volatility)

0.67 (Low)

Price

$6.40

Volume

47,048.714

Open

$6.43

Previous Close

$6.37

Daily Range

$6.20 - $6.54

52-Week Range

$4.31 - $9.56

Estimated Earnings Date

Aug 11, 2026

DERM News

No articles available.

DERM: Motley Fool Moneyball Superscore

49

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Journey Medical

Journey Medical helps people with skin problems like acne and excessive sweating. Its products are used by patients needing prescription treatments for common skin conditions.

Skin Deep: Products and Services

  • Rosacea Treatments: Emrosi and Zilxi target facial redness and bumps.
  • Acne Solutions: Accutane, Amzeeq, Targadox, and Ximino treat moderate to severe acne.
  • Hyperhidrosis Relief: Qbrexza helps control excessive underarm sweating; 40.8% of 2025 revenue.
  • Fungal Infection Care: Exelderm addresses skin fungal infections; part of “other/legacy” revenue.
  • Wound and Itch Products: Luxamend and an anti-itch cream (launch planned 2026) support healing and itch relief.

Growth Spurts: Expansion Moves

  • Launched Emrosi for rosacea in 2025 after FDA approval.
  • Expanded U.S. sales force to cover over 80% of top dermatology markets.
  • Formed partnerships with Dr. Reddy’s Laboratories, Vyne Therapeutics, and Cutia Therapeutics for product development and international supply.
  • Joined the Russell 2000 and Russell 3000 indexes in June 2025.
  • Raised $16.4 million through an at-the-market equity program in 2025.

What Makes Journey Medical Stand Out

Journey Medical focuses on prescription skin treatments with a specialized sales network. Its products reach most U.S. dermatologists through over 600 specialty pharmacies. The company holds patents on key drugs, supporting its position in a competitive market.

Five Things You Need to Know

  • 2025 revenue was $61.9 million, up 10% from 2024.
  • Emrosi contributed 24% of product revenue in its first year (2025).
  • Qbrexza made up 41% of product revenue in 2025, flat year-over-year.
  • Operating loss improved to $(8.2) million in 2025, from $(13.7) million in 2024.
  • Cash and cash equivalents were $24.1 million at December 31, 2025.

Bottom Line

Journey Medical has shifted its portfolio toward newer, patent-protected skin treatments. The company faces ongoing losses but continues to adapt through product launches and partnerships.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

58

CEO

Claude Maraoui

Website

www.journeymedicalcorp.com

Headquarters

Scottsdale, AZ 85258, US

DERM Financials

Key Financial Metrics (TTM)

Gross Margin

60.41%

Operating Margin

-9.80%

Net Income Margin

-14.82%

Return on Equity

-35.57%

Return on Capital

-14.27%

Return on Assets

-10.47%

Earnings Yield

-6.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$175.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

27.53M

Volume

47.05K

Avg. Volume

263.19K

Financials (TTM)

Gross Profit

$39.07M

Operating Income

-$6.34M

EBITDA

-$1.44M

Operating Cash Flow

-$6.70M

Capital Expenditure

$0.00

Free Cash Flow

-$6.70M

Cash & ST Invst.

$27.22M

Total Debt

$25.47M

Journey Medical Performance Analysis

Journey Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 73,669,00016.7%
20232023-12-31USD 79,181,0007.5%
20242024-12-31USD 56,134,000-29.1%
20252025-12-31USD 61,858,00010.2%
Journey Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3014.2%
Q32025-09-3017.5%
Q42025-12-31-8.8%
Q12026-03-31-0.7%
Journey Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.69-33.5%
20232023-12-31USD -0.21-87.5%
20242024-12-31USD -0.72239.8%
20252025-12-31USD -0.47-35.0%
Journey Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3011.1%
Q32025-09-3043.8%
Q42025-12-3149.0%
Q12026-03-31-74.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$15.96M

+21.5%

Gross Profit

$8.62M

+18.3%

Gross Margin

53.99%

N/A

Market Cap

$175.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.02M

N/A

Employees

58

N/A

Net Income

-$2.23M

+45.2%

EBITDA

-$189.00K

+91.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$27.22M

+29.2%

Total Debt

$25.47M

+1.2%

Accounts Receivable

$24.99M

+38.7%

Inventory

$9.29M

-25.6%

Long Term Debt

$22.87M

-1.4%

Short Term Debt

$2.59M

+31.8%

Return on Assets

-10.47%

N/A

Return on Invested Capital

-11.81%

N/A

Free Cash Flow

$2.91M

+202.7%

Operating Cash Flow

$2.91M

+202.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDWDMediWound Ltd.
$14.12+0.14%
OGIOrganigram Global Inc.
$0.94-2.96%
RNACCartesian Therapeutics, Inc.
$7.80+0.91%
IVAInventiva S.A.
$4.48-3.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About DERM

What is the current price of Journey Medical?

Journey Medical is trading at $6.37 per share.

What is the 52-week range for Journey Medical?

Over the past 52 weeks, Journey Medical has traded between $4.31 and $9.56.

How much debt does Journey Medical have?

As of the most recent reporting period, Journey Medical reported total debt of $25.47M.

How much cash does Journey Medical have on hand?

Journey Medical reported $27.22M in cash and cash equivalents in its most recent financial results.

What is Journey Medical’s dividend yield?

Journey Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services